Compounds are provided having the following structure: ##STR00001##
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, L.sup.1, L.sup.2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Compounds are provided having the following structure: ##STR00001##
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, L.sup.1, L.sup.2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

The present invention is directed at mono-, di- or polyquaternary ammonium compounds of the formula (I) wherein x is 1 to 50, and F can be the same or different and is represented by the general formula (II) wherein at least one of the optionally substituted and optionally functional-group-containing hydrocarbon radicals R.sup.1, R.sup.2, R.sup.3, R.sup.4 or R.sup.5 contains at least one estolide moiety comprising two or more ester or amide moieties. The invention also relates to a process for the synthesis of such compounds, the use of the compounds in cosmetic formulations for skin and hair care, cosmetic compositions for the treatment of fibers, and compositions containing one or more of the compounds for the treatment of hair.

##STR00001##

The present invention is directed at mono-, di- or polyquaternary ammonium compounds of the formula (I) wherein x is 1 to 50, and F can be the same or different and is represented by the general formula (II) wherein at least one of the optionally substituted and optionally functional-group-containing hydrocarbon radicals R.sup.1, R.sup.2, R.sup.3, R.sup.4 or R.sup.5 contains at least one estolide moiety comprising two or more ester or amide moieties. The invention also relates to a process for the synthesis of such compounds, the use of the compounds in cosmetic formulations for skin and hair care, cosmetic compositions for the treatment of fibers, and compositions containing one or more of the compounds for the treatment of hair.

##STR00001##

Compounds are provided having the following structure: ##STR00001##
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Compounds are provided having the following structure: ##STR00001##
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Compounds are provided having the following structure: [Formula should be inserted here] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. ##STR00001##

Compounds are provided having the following structure: [Formula should be inserted here] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. ##STR00001##

A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I):

##STR00001##

[in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R.sup.1 and R.sup.2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R.sup.3 and R.sup.4 each independently represents a C.sub.1-4 alkyl group or a C.sub.2-4 alkenyl group, where, R.sup.3 and R.sup.4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C.sub.1-4 alkyl groups or C.sub.2-4 alkenyl groups may be substituted on the ring)].

The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.